Life Technologies Launches Alliance to Evaluate Whole-Genome Sequencing for Guiding Cancer Treatment
June 08, 2010
Life Technologies Launches Alliance to Evaluate Whole-Genome Sequencing for Guiding Cancer Treatment
The alliance is primarily funded by Life Technologies for now and will use the company's SOLiD 4 sequencing platform. Other founding partners include the Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Research Centers Launch Genomic Cancer Care Alliance to Personalize Care via Whole-Genome Sequencing
June 9, 2010 / Pharmacogenomics Reporter - Life Tech, TGen, US Oncology to Partner on Breast Cancer Sequencing Study Aimed at Therapy Advice
March 9, 2010 / In Sequence - IOM Workshop Discusses Interim Strategies to Handle Unresolved Challenges of Clinical Sequencing
July 27, 2011 / Clinical Sequencing News - Life Tech Begins Clinical Trials of CE Sequencer for HLA Typing; Plans 510(k) Clearance
March 22, 2011 / Clinical Sequencing News - In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
January 25, 2011 / In Sequence